Nipocalimab + SoC sustains disease control in patients with myasthenia gravis
19 May 2026
byElaine Soliven
Adding nipocalimab to standard-of-care (SoC) demonstrates sustained disease control through week 120 in adult patients with antibody-positive generalized myasthenia gravis (gMG), including anti-AChR* or anti-MuSK**, according to the Vivacity-MG3 open-label extension (OLE) study presented at AAN 2026.